molecular mass protein standard Search Results


95
Chem Impex International glycerol chem impex
Glycerol Chem Impex, supplied by Chem Impex International, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/glycerol chem impex/product/Chem Impex International
Average 95 stars, based on 1 article reviews
glycerol chem impex - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier

93
KCAS Bioanalytical and Biomarker Services liquid chromatography
Liquid Chromatography, supplied by KCAS Bioanalytical and Biomarker Services, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/liquid chromatography/product/KCAS Bioanalytical and Biomarker Services
Average 93 stars, based on 1 article reviews
liquid chromatography - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

93
Proteintech anti lmp2 psmb9
Anti Lmp2 Psmb9, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti lmp2 psmb9/product/Proteintech
Average 93 stars, based on 1 article reviews
anti lmp2 psmb9 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

93
Proteintech psmb10
Fig. 1 Immunoproteasome expression profile in muscle-invasive bladder cancer (MIBC). A Expression of immunoproteasome subunits PSMB8, PSMB9 and <t>PSMB10</t> in pan-tumor tissues and corresponding normal tissues derived from the TCGA dataset. Red boxes outline upregulation of PSMB8, PSMB9 and PSMB10 in bladder cancer tissues in contrast to normal tissues. Data are expressed as individual spots per subject with mean of the logarithm of transcripts per million. *p < 0.05, **p < 0.01, ***p < 0.001. B Expression of PSMB8, PSMB9 and PSMB10 in MIBC (n = 369) and normal tissues (n = 19) from the TCGA cohort. Data are expressed as individual spots per subject with mean ± SEM of the logarithm of transcripts per million. P-values are indicated in each graph. C Immunohistochemistry staining scores of PSMB8, PSMB9 and PSMB10 in MIBC (n = 67) and normal tissues (n = 18) derived from the CQUCH cohort. Data are expressed as individual spots per subject with mean ± SEM of each group. P-values are indicated in each graph. D Representative positive and negative immunohistochemistry stainings of PSMB8, PSMB9 and PSMB10 in MIBC and normal tissues derived from the CQUCH cohort. Scale bar: 40 μm. Positive stainings are divided into low and high expression by an average immunohistochemistry staining score
Psmb10, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/psmb10/product/Proteintech
Average 93 stars, based on 1 article reviews
psmb10 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

94
Proteintech goat serum
Fig. 1 Immunoproteasome expression profile in muscle-invasive bladder cancer (MIBC). A Expression of immunoproteasome subunits PSMB8, PSMB9 and <t>PSMB10</t> in pan-tumor tissues and corresponding normal tissues derived from the TCGA dataset. Red boxes outline upregulation of PSMB8, PSMB9 and PSMB10 in bladder cancer tissues in contrast to normal tissues. Data are expressed as individual spots per subject with mean of the logarithm of transcripts per million. *p < 0.05, **p < 0.01, ***p < 0.001. B Expression of PSMB8, PSMB9 and PSMB10 in MIBC (n = 369) and normal tissues (n = 19) from the TCGA cohort. Data are expressed as individual spots per subject with mean ± SEM of the logarithm of transcripts per million. P-values are indicated in each graph. C Immunohistochemistry staining scores of PSMB8, PSMB9 and PSMB10 in MIBC (n = 67) and normal tissues (n = 18) derived from the CQUCH cohort. Data are expressed as individual spots per subject with mean ± SEM of each group. P-values are indicated in each graph. D Representative positive and negative immunohistochemistry stainings of PSMB8, PSMB9 and PSMB10 in MIBC and normal tissues derived from the CQUCH cohort. Scale bar: 40 μm. Positive stainings are divided into low and high expression by an average immunohistochemistry staining score
Goat Serum, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/goat serum/product/Proteintech
Average 94 stars, based on 1 article reviews
goat serum - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

90
SERVA Electrophoresis molecular mass standard
Fig. 1 Immunoproteasome expression profile in muscle-invasive bladder cancer (MIBC). A Expression of immunoproteasome subunits PSMB8, PSMB9 and <t>PSMB10</t> in pan-tumor tissues and corresponding normal tissues derived from the TCGA dataset. Red boxes outline upregulation of PSMB8, PSMB9 and PSMB10 in bladder cancer tissues in contrast to normal tissues. Data are expressed as individual spots per subject with mean of the logarithm of transcripts per million. *p < 0.05, **p < 0.01, ***p < 0.001. B Expression of PSMB8, PSMB9 and PSMB10 in MIBC (n = 369) and normal tissues (n = 19) from the TCGA cohort. Data are expressed as individual spots per subject with mean ± SEM of the logarithm of transcripts per million. P-values are indicated in each graph. C Immunohistochemistry staining scores of PSMB8, PSMB9 and PSMB10 in MIBC (n = 67) and normal tissues (n = 18) derived from the CQUCH cohort. Data are expressed as individual spots per subject with mean ± SEM of each group. P-values are indicated in each graph. D Representative positive and negative immunohistochemistry stainings of PSMB8, PSMB9 and PSMB10 in MIBC and normal tissues derived from the CQUCH cohort. Scale bar: 40 μm. Positive stainings are divided into low and high expression by an average immunohistochemistry staining score
Molecular Mass Standard, supplied by SERVA Electrophoresis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/molecular mass standard/product/SERVA Electrophoresis
Average 90 stars, based on 1 article reviews
molecular mass standard - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Bruker Corporation protein molecular weight calibration standard 1
Fig. 1 Immunoproteasome expression profile in muscle-invasive bladder cancer (MIBC). A Expression of immunoproteasome subunits PSMB8, PSMB9 and <t>PSMB10</t> in pan-tumor tissues and corresponding normal tissues derived from the TCGA dataset. Red boxes outline upregulation of PSMB8, PSMB9 and PSMB10 in bladder cancer tissues in contrast to normal tissues. Data are expressed as individual spots per subject with mean of the logarithm of transcripts per million. *p < 0.05, **p < 0.01, ***p < 0.001. B Expression of PSMB8, PSMB9 and PSMB10 in MIBC (n = 369) and normal tissues (n = 19) from the TCGA cohort. Data are expressed as individual spots per subject with mean ± SEM of the logarithm of transcripts per million. P-values are indicated in each graph. C Immunohistochemistry staining scores of PSMB8, PSMB9 and PSMB10 in MIBC (n = 67) and normal tissues (n = 18) derived from the CQUCH cohort. Data are expressed as individual spots per subject with mean ± SEM of each group. P-values are indicated in each graph. D Representative positive and negative immunohistochemistry stainings of PSMB8, PSMB9 and PSMB10 in MIBC and normal tissues derived from the CQUCH cohort. Scale bar: 40 μm. Positive stainings are divided into low and high expression by an average immunohistochemistry staining score
Protein Molecular Weight Calibration Standard 1, supplied by Bruker Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/protein molecular weight calibration standard 1/product/Bruker Corporation
Average 90 stars, based on 1 article reviews
protein molecular weight calibration standard 1 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Amersham Life Sciences Inc molecular-weight protein standards
Fig. 1 Immunoproteasome expression profile in muscle-invasive bladder cancer (MIBC). A Expression of immunoproteasome subunits PSMB8, PSMB9 and <t>PSMB10</t> in pan-tumor tissues and corresponding normal tissues derived from the TCGA dataset. Red boxes outline upregulation of PSMB8, PSMB9 and PSMB10 in bladder cancer tissues in contrast to normal tissues. Data are expressed as individual spots per subject with mean of the logarithm of transcripts per million. *p < 0.05, **p < 0.01, ***p < 0.001. B Expression of PSMB8, PSMB9 and PSMB10 in MIBC (n = 369) and normal tissues (n = 19) from the TCGA cohort. Data are expressed as individual spots per subject with mean ± SEM of the logarithm of transcripts per million. P-values are indicated in each graph. C Immunohistochemistry staining scores of PSMB8, PSMB9 and PSMB10 in MIBC (n = 67) and normal tissues (n = 18) derived from the CQUCH cohort. Data are expressed as individual spots per subject with mean ± SEM of each group. P-values are indicated in each graph. D Representative positive and negative immunohistochemistry stainings of PSMB8, PSMB9 and PSMB10 in MIBC and normal tissues derived from the CQUCH cohort. Scale bar: 40 μm. Positive stainings are divided into low and high expression by an average immunohistochemistry staining score
Molecular Weight Protein Standards, supplied by Amersham Life Sciences Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/molecular-weight protein standards/product/Amersham Life Sciences Inc
Average 90 stars, based on 1 article reviews
molecular-weight protein standards - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Pharmacia LKB Biotechnology Inc molecular weight marker pharmacia lkb
Fig. 1 Immunoproteasome expression profile in muscle-invasive bladder cancer (MIBC). A Expression of immunoproteasome subunits PSMB8, PSMB9 and <t>PSMB10</t> in pan-tumor tissues and corresponding normal tissues derived from the TCGA dataset. Red boxes outline upregulation of PSMB8, PSMB9 and PSMB10 in bladder cancer tissues in contrast to normal tissues. Data are expressed as individual spots per subject with mean of the logarithm of transcripts per million. *p < 0.05, **p < 0.01, ***p < 0.001. B Expression of PSMB8, PSMB9 and PSMB10 in MIBC (n = 369) and normal tissues (n = 19) from the TCGA cohort. Data are expressed as individual spots per subject with mean ± SEM of the logarithm of transcripts per million. P-values are indicated in each graph. C Immunohistochemistry staining scores of PSMB8, PSMB9 and PSMB10 in MIBC (n = 67) and normal tissues (n = 18) derived from the CQUCH cohort. Data are expressed as individual spots per subject with mean ± SEM of each group. P-values are indicated in each graph. D Representative positive and negative immunohistochemistry stainings of PSMB8, PSMB9 and PSMB10 in MIBC and normal tissues derived from the CQUCH cohort. Scale bar: 40 μm. Positive stainings are divided into low and high expression by an average immunohistochemistry staining score
Molecular Weight Marker Pharmacia Lkb, supplied by Pharmacia LKB Biotechnology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/molecular weight marker pharmacia lkb/product/Pharmacia LKB Biotechnology Inc
Average 90 stars, based on 1 article reviews
molecular weight marker pharmacia lkb - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Fisher Scientific molecular mass ladder pagerulertm plus prestained protein ladder, 10 to 250 kda
Fig. 1 Immunoproteasome expression profile in muscle-invasive bladder cancer (MIBC). A Expression of immunoproteasome subunits PSMB8, PSMB9 and <t>PSMB10</t> in pan-tumor tissues and corresponding normal tissues derived from the TCGA dataset. Red boxes outline upregulation of PSMB8, PSMB9 and PSMB10 in bladder cancer tissues in contrast to normal tissues. Data are expressed as individual spots per subject with mean of the logarithm of transcripts per million. *p < 0.05, **p < 0.01, ***p < 0.001. B Expression of PSMB8, PSMB9 and PSMB10 in MIBC (n = 369) and normal tissues (n = 19) from the TCGA cohort. Data are expressed as individual spots per subject with mean ± SEM of the logarithm of transcripts per million. P-values are indicated in each graph. C Immunohistochemistry staining scores of PSMB8, PSMB9 and PSMB10 in MIBC (n = 67) and normal tissues (n = 18) derived from the CQUCH cohort. Data are expressed as individual spots per subject with mean ± SEM of each group. P-values are indicated in each graph. D Representative positive and negative immunohistochemistry stainings of PSMB8, PSMB9 and PSMB10 in MIBC and normal tissues derived from the CQUCH cohort. Scale bar: 40 μm. Positive stainings are divided into low and high expression by an average immunohistochemistry staining score
Molecular Mass Ladder Pagerulertm Plus Prestained Protein Ladder, 10 To 250 Kda, supplied by Fisher Scientific, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/molecular mass ladder pagerulertm plus prestained protein ladder, 10 to 250 kda/product/Fisher Scientific
Average 90 stars, based on 1 article reviews
molecular mass ladder pagerulertm plus prestained protein ladder, 10 to 250 kda - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
NZYTech Inc molecular weight markers nzycolour protein marker ii
Fig. 1 Immunoproteasome expression profile in muscle-invasive bladder cancer (MIBC). A Expression of immunoproteasome subunits PSMB8, PSMB9 and <t>PSMB10</t> in pan-tumor tissues and corresponding normal tissues derived from the TCGA dataset. Red boxes outline upregulation of PSMB8, PSMB9 and PSMB10 in bladder cancer tissues in contrast to normal tissues. Data are expressed as individual spots per subject with mean of the logarithm of transcripts per million. *p < 0.05, **p < 0.01, ***p < 0.001. B Expression of PSMB8, PSMB9 and PSMB10 in MIBC (n = 369) and normal tissues (n = 19) from the TCGA cohort. Data are expressed as individual spots per subject with mean ± SEM of the logarithm of transcripts per million. P-values are indicated in each graph. C Immunohistochemistry staining scores of PSMB8, PSMB9 and PSMB10 in MIBC (n = 67) and normal tissues (n = 18) derived from the CQUCH cohort. Data are expressed as individual spots per subject with mean ± SEM of each group. P-values are indicated in each graph. D Representative positive and negative immunohistochemistry stainings of PSMB8, PSMB9 and PSMB10 in MIBC and normal tissues derived from the CQUCH cohort. Scale bar: 40 μm. Positive stainings are divided into low and high expression by an average immunohistochemistry staining score
Molecular Weight Markers Nzycolour Protein Marker Ii, supplied by NZYTech Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/molecular weight markers nzycolour protein marker ii/product/NZYTech Inc
Average 90 stars, based on 1 article reviews
molecular weight markers nzycolour protein marker ii - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Fluka Chemical molecular weight markers
Fig. 1 Immunoproteasome expression profile in muscle-invasive bladder cancer (MIBC). A Expression of immunoproteasome subunits PSMB8, PSMB9 and <t>PSMB10</t> in pan-tumor tissues and corresponding normal tissues derived from the TCGA dataset. Red boxes outline upregulation of PSMB8, PSMB9 and PSMB10 in bladder cancer tissues in contrast to normal tissues. Data are expressed as individual spots per subject with mean of the logarithm of transcripts per million. *p < 0.05, **p < 0.01, ***p < 0.001. B Expression of PSMB8, PSMB9 and PSMB10 in MIBC (n = 369) and normal tissues (n = 19) from the TCGA cohort. Data are expressed as individual spots per subject with mean ± SEM of the logarithm of transcripts per million. P-values are indicated in each graph. C Immunohistochemistry staining scores of PSMB8, PSMB9 and PSMB10 in MIBC (n = 67) and normal tissues (n = 18) derived from the CQUCH cohort. Data are expressed as individual spots per subject with mean ± SEM of each group. P-values are indicated in each graph. D Representative positive and negative immunohistochemistry stainings of PSMB8, PSMB9 and PSMB10 in MIBC and normal tissues derived from the CQUCH cohort. Scale bar: 40 μm. Positive stainings are divided into low and high expression by an average immunohistochemistry staining score
Molecular Weight Markers, supplied by Fluka Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/molecular weight markers/product/Fluka Chemical
Average 90 stars, based on 1 article reviews
molecular weight markers - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Fig. 1 Immunoproteasome expression profile in muscle-invasive bladder cancer (MIBC). A Expression of immunoproteasome subunits PSMB8, PSMB9 and PSMB10 in pan-tumor tissues and corresponding normal tissues derived from the TCGA dataset. Red boxes outline upregulation of PSMB8, PSMB9 and PSMB10 in bladder cancer tissues in contrast to normal tissues. Data are expressed as individual spots per subject with mean of the logarithm of transcripts per million. *p < 0.05, **p < 0.01, ***p < 0.001. B Expression of PSMB8, PSMB9 and PSMB10 in MIBC (n = 369) and normal tissues (n = 19) from the TCGA cohort. Data are expressed as individual spots per subject with mean ± SEM of the logarithm of transcripts per million. P-values are indicated in each graph. C Immunohistochemistry staining scores of PSMB8, PSMB9 and PSMB10 in MIBC (n = 67) and normal tissues (n = 18) derived from the CQUCH cohort. Data are expressed as individual spots per subject with mean ± SEM of each group. P-values are indicated in each graph. D Representative positive and negative immunohistochemistry stainings of PSMB8, PSMB9 and PSMB10 in MIBC and normal tissues derived from the CQUCH cohort. Scale bar: 40 μm. Positive stainings are divided into low and high expression by an average immunohistochemistry staining score

Journal: Journal of translational medicine

Article Title: Immunoproteasome subunits are novel signatures for predicting efficacy of immunotherapy in muscle invasive bladder cancer.

doi: 10.1186/s12967-025-06207-w

Figure Lengend Snippet: Fig. 1 Immunoproteasome expression profile in muscle-invasive bladder cancer (MIBC). A Expression of immunoproteasome subunits PSMB8, PSMB9 and PSMB10 in pan-tumor tissues and corresponding normal tissues derived from the TCGA dataset. Red boxes outline upregulation of PSMB8, PSMB9 and PSMB10 in bladder cancer tissues in contrast to normal tissues. Data are expressed as individual spots per subject with mean of the logarithm of transcripts per million. *p < 0.05, **p < 0.01, ***p < 0.001. B Expression of PSMB8, PSMB9 and PSMB10 in MIBC (n = 369) and normal tissues (n = 19) from the TCGA cohort. Data are expressed as individual spots per subject with mean ± SEM of the logarithm of transcripts per million. P-values are indicated in each graph. C Immunohistochemistry staining scores of PSMB8, PSMB9 and PSMB10 in MIBC (n = 67) and normal tissues (n = 18) derived from the CQUCH cohort. Data are expressed as individual spots per subject with mean ± SEM of each group. P-values are indicated in each graph. D Representative positive and negative immunohistochemistry stainings of PSMB8, PSMB9 and PSMB10 in MIBC and normal tissues derived from the CQUCH cohort. Scale bar: 40 μm. Positive stainings are divided into low and high expression by an average immunohistochemistry staining score

Article Snippet: Following incubation in phosphate-buffered saline containing 10% species-appropriate normal serum to block non-specific binding at room temperature for 1 h, sections were incubated in a humidified chamber with primary antibodies against PSMB8 (1:100; proteintech, Wuhan, China), PSMB9 (1:100; proteintech), PSMB10 (1:100; proteintech) and PD-L1 (1:100; proteintech) using isotype-matched IgGs as negative controls at 4 °C overnight.

Techniques: Expressing, Derivative Assay, Immunohistochemistry, Staining

Fig. 2 Association of the expression of immunoproteasome subunits with survival prognosis in MIBC patients. A Kaplan–Meier curve of progression-free survival (upper panel) and overall survival (lower panel) for MIBC patients in the CQUCH cohort with high and low expression of PSMB8, PSMB9 and PSMB10. B Kaplan–Meier curve of progression-free survival (upper panel) and overall survival (lower panel) for MIBC patients in the TCGA cohort with high and low expression of PSMB8, PSMB9 and PSMB10

Journal: Journal of translational medicine

Article Title: Immunoproteasome subunits are novel signatures for predicting efficacy of immunotherapy in muscle invasive bladder cancer.

doi: 10.1186/s12967-025-06207-w

Figure Lengend Snippet: Fig. 2 Association of the expression of immunoproteasome subunits with survival prognosis in MIBC patients. A Kaplan–Meier curve of progression-free survival (upper panel) and overall survival (lower panel) for MIBC patients in the CQUCH cohort with high and low expression of PSMB8, PSMB9 and PSMB10. B Kaplan–Meier curve of progression-free survival (upper panel) and overall survival (lower panel) for MIBC patients in the TCGA cohort with high and low expression of PSMB8, PSMB9 and PSMB10

Article Snippet: Following incubation in phosphate-buffered saline containing 10% species-appropriate normal serum to block non-specific binding at room temperature for 1 h, sections were incubated in a humidified chamber with primary antibodies against PSMB8 (1:100; proteintech, Wuhan, China), PSMB9 (1:100; proteintech), PSMB10 (1:100; proteintech) and PD-L1 (1:100; proteintech) using isotype-matched IgGs as negative controls at 4 °C overnight.

Techniques: Expressing

Fig. 3 Association of the expression of immunoproteasome subunits with survival prognosis in MIBC patients receiving immunotherapy. A Kaplan–Meier curve of overall survival for MIBC patients receiving immune checkpoint inhibitor treatment in the IMvigor210 cohort with high and low expression of PSMB8, PSMB9 and PSMB10. B Kaplan–Meier curve of progression-free survival (upper panel) and overall survival (lower panel) for MIBC patients receiving immune checkpoint inhibitor treatment in the CQUCH cohort with high and low expression of PSMB8, PSMB9 and PSMB10

Journal: Journal of translational medicine

Article Title: Immunoproteasome subunits are novel signatures for predicting efficacy of immunotherapy in muscle invasive bladder cancer.

doi: 10.1186/s12967-025-06207-w

Figure Lengend Snippet: Fig. 3 Association of the expression of immunoproteasome subunits with survival prognosis in MIBC patients receiving immunotherapy. A Kaplan–Meier curve of overall survival for MIBC patients receiving immune checkpoint inhibitor treatment in the IMvigor210 cohort with high and low expression of PSMB8, PSMB9 and PSMB10. B Kaplan–Meier curve of progression-free survival (upper panel) and overall survival (lower panel) for MIBC patients receiving immune checkpoint inhibitor treatment in the CQUCH cohort with high and low expression of PSMB8, PSMB9 and PSMB10

Article Snippet: Following incubation in phosphate-buffered saline containing 10% species-appropriate normal serum to block non-specific binding at room temperature for 1 h, sections were incubated in a humidified chamber with primary antibodies against PSMB8 (1:100; proteintech, Wuhan, China), PSMB9 (1:100; proteintech), PSMB10 (1:100; proteintech) and PD-L1 (1:100; proteintech) using isotype-matched IgGs as negative controls at 4 °C overnight.

Techniques: Expressing

Fig. 4 Effect of immunotherapy (IMT) on survival prognosis in MIBC patients with different expression levels of immunoproteasome subunits. A Kaplan–Meier curve of progression-free survival (upper panel) and overall survival (lower panel) for MIBC patients receiving IMT or not receiving (non-IMT) immune checkpoint inhibitor treatment in the CQUCH cohort with high expression of PSMB8, PSMB9 and PSMB10. B Kaplan–Meier curve of progression-free survival (upper panel) and overall survival (lower panel) for MIBC patients receiving IMT or not receiving (non-IMT) immune checkpoint inhibitor treatment in the CQUCH cohort with low expression of PSMB8, PSMB9 and PSMB10

Journal: Journal of translational medicine

Article Title: Immunoproteasome subunits are novel signatures for predicting efficacy of immunotherapy in muscle invasive bladder cancer.

doi: 10.1186/s12967-025-06207-w

Figure Lengend Snippet: Fig. 4 Effect of immunotherapy (IMT) on survival prognosis in MIBC patients with different expression levels of immunoproteasome subunits. A Kaplan–Meier curve of progression-free survival (upper panel) and overall survival (lower panel) for MIBC patients receiving IMT or not receiving (non-IMT) immune checkpoint inhibitor treatment in the CQUCH cohort with high expression of PSMB8, PSMB9 and PSMB10. B Kaplan–Meier curve of progression-free survival (upper panel) and overall survival (lower panel) for MIBC patients receiving IMT or not receiving (non-IMT) immune checkpoint inhibitor treatment in the CQUCH cohort with low expression of PSMB8, PSMB9 and PSMB10

Article Snippet: Following incubation in phosphate-buffered saline containing 10% species-appropriate normal serum to block non-specific binding at room temperature for 1 h, sections were incubated in a humidified chamber with primary antibodies against PSMB8 (1:100; proteintech, Wuhan, China), PSMB9 (1:100; proteintech), PSMB10 (1:100; proteintech) and PD-L1 (1:100; proteintech) using isotype-matched IgGs as negative controls at 4 °C overnight.

Techniques: Expressing

Fig. 6 Association of immunoproteasome subunits with inflammatory factors in MIBC. Expression correlation heatmap of the association of IFN-γ and TNF with the immunoproteasome subunits PSMB8, PSMB9 and PSMB10 in MIBC of the TCGA cohort (A) and the IMvigor210 cohort (B). Correlation coefficient between each two molecules is written in each square. Color bar on the right side of each heatmap shows the correlation coefficient. Positive correlation is shown in red, negative and blue. C, D Kaplan–Meier curve of overall survival of MIBC patients receiving immune checkpoint inhibitor treatment in the IMvigor210 cohort with high and low expression of IFN-γ or TNF

Journal: Journal of translational medicine

Article Title: Immunoproteasome subunits are novel signatures for predicting efficacy of immunotherapy in muscle invasive bladder cancer.

doi: 10.1186/s12967-025-06207-w

Figure Lengend Snippet: Fig. 6 Association of immunoproteasome subunits with inflammatory factors in MIBC. Expression correlation heatmap of the association of IFN-γ and TNF with the immunoproteasome subunits PSMB8, PSMB9 and PSMB10 in MIBC of the TCGA cohort (A) and the IMvigor210 cohort (B). Correlation coefficient between each two molecules is written in each square. Color bar on the right side of each heatmap shows the correlation coefficient. Positive correlation is shown in red, negative and blue. C, D Kaplan–Meier curve of overall survival of MIBC patients receiving immune checkpoint inhibitor treatment in the IMvigor210 cohort with high and low expression of IFN-γ or TNF

Article Snippet: Following incubation in phosphate-buffered saline containing 10% species-appropriate normal serum to block non-specific binding at room temperature for 1 h, sections were incubated in a humidified chamber with primary antibodies against PSMB8 (1:100; proteintech, Wuhan, China), PSMB9 (1:100; proteintech), PSMB10 (1:100; proteintech) and PD-L1 (1:100; proteintech) using isotype-matched IgGs as negative controls at 4 °C overnight.

Techniques: Expressing

Fig. 7 Association of immunoproteasome subunits with tumor infiltrating immune cells in MIBC. Correlation lollipop charts of tumor infiltrating immune cells which were associated with the expression of the immunoproteasome subunits PSMB8, PSMB9 and PSMB10 in MIBC of the TCGA cohort (A) and the IMvigor210 cohort (B). Lollipop size shows the correlation coefficient between each infiltrating immune cell type and each immunoproteasome subunit. P values were labeled on the right side of each chart. Values of P < 0.05 were considered statistically significant and marked in red

Journal: Journal of translational medicine

Article Title: Immunoproteasome subunits are novel signatures for predicting efficacy of immunotherapy in muscle invasive bladder cancer.

doi: 10.1186/s12967-025-06207-w

Figure Lengend Snippet: Fig. 7 Association of immunoproteasome subunits with tumor infiltrating immune cells in MIBC. Correlation lollipop charts of tumor infiltrating immune cells which were associated with the expression of the immunoproteasome subunits PSMB8, PSMB9 and PSMB10 in MIBC of the TCGA cohort (A) and the IMvigor210 cohort (B). Lollipop size shows the correlation coefficient between each infiltrating immune cell type and each immunoproteasome subunit. P values were labeled on the right side of each chart. Values of P < 0.05 were considered statistically significant and marked in red

Article Snippet: Following incubation in phosphate-buffered saline containing 10% species-appropriate normal serum to block non-specific binding at room temperature for 1 h, sections were incubated in a humidified chamber with primary antibodies against PSMB8 (1:100; proteintech, Wuhan, China), PSMB9 (1:100; proteintech), PSMB10 (1:100; proteintech) and PD-L1 (1:100; proteintech) using isotype-matched IgGs as negative controls at 4 °C overnight.

Techniques: Expressing, Labeling

Fig. 8 Association of immunoproteasome subunits with different immune-related functions and signaling in MIBC. A GO analysis of the association of the immunoproteasome subunits PSMB8, PSMB9 and PSMB10 with immune-related functions in MIBC of the TCGA cohort. Color bar shows the p-value on the right side of each chart. The number of related genes were shown as the length of the column of each chart. B KEGG analysis of the association of the immunoproteasome subunits PSMB8, PSMB9 and PSMB10 with immune-related signaling in MIBC of the TCGA cohort. Color bar shows the p-value on the right side of each chart. The number of related genes were shown by dot size. C GSEA analysis of the association of the immunoproteasome subunits PSMB8, PSMB9 and PSMB10 with different immune cell functions in MIBC of the TCGA cohort

Journal: Journal of translational medicine

Article Title: Immunoproteasome subunits are novel signatures for predicting efficacy of immunotherapy in muscle invasive bladder cancer.

doi: 10.1186/s12967-025-06207-w

Figure Lengend Snippet: Fig. 8 Association of immunoproteasome subunits with different immune-related functions and signaling in MIBC. A GO analysis of the association of the immunoproteasome subunits PSMB8, PSMB9 and PSMB10 with immune-related functions in MIBC of the TCGA cohort. Color bar shows the p-value on the right side of each chart. The number of related genes were shown as the length of the column of each chart. B KEGG analysis of the association of the immunoproteasome subunits PSMB8, PSMB9 and PSMB10 with immune-related signaling in MIBC of the TCGA cohort. Color bar shows the p-value on the right side of each chart. The number of related genes were shown by dot size. C GSEA analysis of the association of the immunoproteasome subunits PSMB8, PSMB9 and PSMB10 with different immune cell functions in MIBC of the TCGA cohort

Article Snippet: Following incubation in phosphate-buffered saline containing 10% species-appropriate normal serum to block non-specific binding at room temperature for 1 h, sections were incubated in a humidified chamber with primary antibodies against PSMB8 (1:100; proteintech, Wuhan, China), PSMB9 (1:100; proteintech), PSMB10 (1:100; proteintech) and PD-L1 (1:100; proteintech) using isotype-matched IgGs as negative controls at 4 °C overnight.

Techniques: